Neurocrine (NBIX) Earnings Preview: Mizuho Models Sales of $288.2M, Seeks Clarity on Post-COVID Recovery, Reiterates Neutral Rating with $95 Price Target
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Neutral rating and $95.00 price target on Neurocrine Bio. (NASDAQ: NBIX), ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
